Limits...
Restored expression levels of TET1 decrease the proliferation and migration of renal carcinoma cells.

Fan M, He X, Xu X - Mol Med Rep (2015)

Bottom Line: Ten‑eleven translocation methylcytosine dioxygenase 1 (TET1) is a member of the TET family of enzymes, and is expressed at low levels in multiple malignancies.As a result, TET1 was observed to exhibit markedly low expression levels in 54 tumor tissue samples from 54 patients with renal carcinoma.In conclusion, the results demonstrated that TET1 is involved in tumor inhibition in renal carcinoma by promoting cell apoptosis and inhibiting cell proliferation and invasion, which may be exploited as a novel therapeutic target in the treatment of renal carcinoma.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, The First People's Hospital of Changzhou, Changzhou, Jiangsu 213003, P.R. China.

ABSTRACT
Renal carcinoma is the most common type of kidney cancer in adults and is responsible for ~90‑95% of the cases of kidney cancer. Ten‑eleven translocation methylcytosine dioxygenase 1 (TET1) is a member of the TET family of enzymes, and is expressed at low levels in multiple malignancies. In the present study, a series of experiments were designed and performed to investigate whether the expression of TET1 is clinically correlated with clinical outcomes in renal carcinoma, and to examine the associations between TET1 expression level and the proliferation and migration in renal carcinoma cells. As a result, TET1 was observed to exhibit markedly low expression levels in 54 tumor tissue samples from 54 patients with renal carcinoma. Furthermore, statistical analysis revealed a clinical correlation between low expression levels of TET1 and the prognosis of patients with renal carcinoma. When TET1 was overexpressed in renal carcinoma cells, the viability and invasive abilities of the cells were decreased, and the rate of apoptosis was increased. In conclusion, the results demonstrated that TET1 is involved in tumor inhibition in renal carcinoma by promoting cell apoptosis and inhibiting cell proliferation and invasion, which may be exploited as a novel therapeutic target in the treatment of renal carcinoma.

Show MeSH

Related in: MedlinePlus

Kaplan-Meier curves of survival durations in patients with renal carcinoma, according to the expression levels of TET1. *P<0.05, compared with the high TET1 expression group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4581741&req=5

f2-mmr-12-04-4837: Kaplan-Meier curves of survival durations in patients with renal carcinoma, according to the expression levels of TET1. *P<0.05, compared with the high TET1 expression group.

Mentions: The statistical analyses demonstrated that the expression level of TET1 correlated negatively with the grade of the tumor. Univariate survival analysis revealed significant associations (P<0.05) between the patient prognosis, the tumor size and the expression levels of TET1. However, no significant associations were observed among genders or ages at diagnosis. The survival probability was reduced in patients with renal carcinoma tissues exhibiting lower expression levels of TET1 (Fig. 2).


Restored expression levels of TET1 decrease the proliferation and migration of renal carcinoma cells.

Fan M, He X, Xu X - Mol Med Rep (2015)

Kaplan-Meier curves of survival durations in patients with renal carcinoma, according to the expression levels of TET1. *P<0.05, compared with the high TET1 expression group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4581741&req=5

f2-mmr-12-04-4837: Kaplan-Meier curves of survival durations in patients with renal carcinoma, according to the expression levels of TET1. *P<0.05, compared with the high TET1 expression group.
Mentions: The statistical analyses demonstrated that the expression level of TET1 correlated negatively with the grade of the tumor. Univariate survival analysis revealed significant associations (P<0.05) between the patient prognosis, the tumor size and the expression levels of TET1. However, no significant associations were observed among genders or ages at diagnosis. The survival probability was reduced in patients with renal carcinoma tissues exhibiting lower expression levels of TET1 (Fig. 2).

Bottom Line: Ten‑eleven translocation methylcytosine dioxygenase 1 (TET1) is a member of the TET family of enzymes, and is expressed at low levels in multiple malignancies.As a result, TET1 was observed to exhibit markedly low expression levels in 54 tumor tissue samples from 54 patients with renal carcinoma.In conclusion, the results demonstrated that TET1 is involved in tumor inhibition in renal carcinoma by promoting cell apoptosis and inhibiting cell proliferation and invasion, which may be exploited as a novel therapeutic target in the treatment of renal carcinoma.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, The First People's Hospital of Changzhou, Changzhou, Jiangsu 213003, P.R. China.

ABSTRACT
Renal carcinoma is the most common type of kidney cancer in adults and is responsible for ~90‑95% of the cases of kidney cancer. Ten‑eleven translocation methylcytosine dioxygenase 1 (TET1) is a member of the TET family of enzymes, and is expressed at low levels in multiple malignancies. In the present study, a series of experiments were designed and performed to investigate whether the expression of TET1 is clinically correlated with clinical outcomes in renal carcinoma, and to examine the associations between TET1 expression level and the proliferation and migration in renal carcinoma cells. As a result, TET1 was observed to exhibit markedly low expression levels in 54 tumor tissue samples from 54 patients with renal carcinoma. Furthermore, statistical analysis revealed a clinical correlation between low expression levels of TET1 and the prognosis of patients with renal carcinoma. When TET1 was overexpressed in renal carcinoma cells, the viability and invasive abilities of the cells were decreased, and the rate of apoptosis was increased. In conclusion, the results demonstrated that TET1 is involved in tumor inhibition in renal carcinoma by promoting cell apoptosis and inhibiting cell proliferation and invasion, which may be exploited as a novel therapeutic target in the treatment of renal carcinoma.

Show MeSH
Related in: MedlinePlus